|
|
低密度 |
|
| 变量 |
四分位数1(< 1.74更易/ L) |
四分位数2(1.74 - -2.15更易/ L) |
象限3(2.15 - -2.67更易/ L) |
象限4(> 2.67更易/ L) |
价值 |
|
| 男,(%) |
701 (57.2) |
593 (49.6) |
542 (45.7) |
509 (42.6) |
< 0.001 |
| 年龄、年 |
60.6±10.7 |
59.9±10.6 |
59.5±10.9 |
58.1±11.2 |
< 0.001 |
| BMI,公斤/米2 |
24.3±3.4 |
24.6±3.3 |
24.7±3.2 |
24.7±3.4 |
0.285 |
| HTN,(%) |
854 (69.7) |
845 (70.7) |
862 (72.6) |
767 (64.2) |
0.017 |
| DM,(%) |
829 (67.6) |
624 (52.2) |
582 (49.0) |
602 (50.4) |
< 0.001 |
| 胰岛素 |
262 (21.4) |
178 (14.9) |
166 (14.0) |
176 (14.7) |
< 0.001 |
| 口服药物治疗 |
769 (62.7) |
564 (47.2) |
499 (42.0) |
515 (43.1) |
< 0.001 |
| 新诊断的 |
40 (3.3) |
49 (4.1) |
66 (5.6) |
69 (5.8) |
0.001 |
| 慢性肾病,(%) |
116 (9.5) |
114 (9.5) |
106 (8.9) |
111 (9.3) |
0.770 |
| 表皮生长因子受体,毫升/分钟 |
92.2±30.1 |
92.4±29.1 |
90.4±27.3 |
89.9±27.1 |
0.102 |
| 高频,(%) |
73 (6.0) |
56 (4.7) |
52 (4.4) |
51 (4.3) |
0.051 |
| 持续性房颤,(%) |
41 (3.3) |
47 (3.9) |
44 (3.7) |
43 (3.6) |
0.815 |
| 心绞痛,(%) |
342 (27.9) |
353 (29.5) |
320 (27.0) |
277 (23.2) |
0.004 |
| 胸痛、(%) |
302 (24.6) |
303 (25.3) |
279 (23.5) |
235 (19.7) |
0.002 |
| 血管痉挛的心绞痛,(%) |
40 (3.3) |
50 (4.2) |
41 (3.5) |
42 (3.5) |
0.978 |
|
| 实验室结果 |
| TC,更易与L |
3.13±0.47 |
3.65±0.36 |
4.14±0.36 |
5.21±0.75 |
< 0.001 |
| TG,更易与L |
1.36±1.02 |
1.39±0.86 |
1.56±0.95 |
1.83±0.97 |
< 0.001 |
| 高密度脂蛋白胆固醇,更易与L |
1.30±0.36 |
1.32±0.31 |
1.35±0.31 |
1.37±0.34 |
< 0.001 |
| 低密度,更易与L |
1.42±0.26 |
1.94±0.13 |
2.41±0.16 |
3.37±0.62 |
< 0.001 |
| hsCRP, nmol / L |
31.43±95.24 |
23.81±79.05 |
24.76±106.67 |
28.57±89.53 |
0.156 |
| 空腹血糖,更易与L |
6.88±2.05 |
6.66±2.05 |
6.66±2.11 |
6.83±2.61 |
0.018 |
| 糖化血红蛋白,% |
6.9±1.2 |
6.7±1.2 |
6.7±1.3 |
6.8±1.3 |
0.002 |
| 铬、μ摩尔/升 |
76.3±83.9 |
76.3±91.5 |
76.3±91.5 |
76.3±83.9 |
0.949 |
| 脂蛋白(a),μ更易与L |
0.71±0.71 |
0.93±1.00 |
1.07±1.07 |
1.25±1.36 |
< 0.001 |
| Apo -ⅰ,g / L |
1.34±0.28 |
1.41±0.25 |
1.45±0.22 |
1.49±0.26 |
< 0.001 |
| Apo B, g / L |
0.50±0.10 |
0.62±0.09 |
0.74±0.10 |
0.95±0.19 |
< 0.001 |
| Apo C-II, g / L |
0.03±0.01 |
0.04±0.02 |
0.04±0.02 |
0.05±0.02 |
< 0.001 |
| Apo E, g / L |
0.02±0.018 |
0.03±0.01 |
0.03±0.01 |
0.04±0.01 |
< 0.001 |
|
| 他汀类药物的类型 |
|
|
|
|
< 0.001 |
| 阿托伐他汀,(%) |
617 (50.3) |
650 (54.3) |
601 (50.6) |
535 (44.8) |
|
| 辛伐他汀,(%) |
251 (20.5) |
243 (20.3) |
243 (20.5) |
274 (22.9) |
|
| 伐(%) |
243 (19.8) |
175 (14.6) |
145 (12.2) |
191 (16.0) |
|
| Pitavastatin,(%) |
60 (4.9) |
70例(5.9%) |
103例(8.7%) |
88 (7.4) |
|
| 普伐他汀,(%) |
25 (2.0) |
34 (2.8) |
51 (4.3) |
67 (5.6) |
|
| Fluvastatin,(%) |
30 (2.4) |
24 (2.0) |
44 (3.7) |
39 (3.3) |
|
| 后续,天 |
1639±751 |
1682±769 |
1792±755 |
1887±803 |
< 0.001 |
|
|
|
低密度脂蛋白、低密度脂蛋白胆固醇;体重指数、体重指数;HTN、高血压;糖尿病、糖尿病;CKD,慢性肾脏疾病;表皮生长因子受体,估计肾小球滤过率;心力衰竭、心力衰竭;心房颤动、心房纤维性颤动;TC、总胆固醇;TG,甘油三酸酯; HDL-C, high-density lipoprotein cholesterol; hsCRP, high-sensitivity C-reactive protein; HbA1c, glycated hemoglobin; Cr, creatinine; Apo, apolipoprotein.
|
